33 related articles for article (PubMed ID: 38082106)
1. A novel ARIH1::BRAF fusion in a glioma.
Xu E; Stone SL; Zhong Y; Golenberg N; Qiu L; Abdullaev Z; Aldape K; Bagley L; Halpern CH; Amankulor N; Nasrallah MP
J Neuropathol Exp Neurol; 2023 Oct; 82(11):966-969. PubMed ID: 37742132
[No Abstract] [Full Text] [Related]
2. Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Kilburn LB; Khuong-Quang DA; Hansford JR; Landi D; van der Lugt J; Leary SES; Driever PH; Bailey S; Perreault S; McCowage G; Waanders AJ; Ziegler DS; Witt O; Baxter PA; Kang HJ; Hassall TE; Han JW; Hargrave D; Franson AT; Yalon Oren M; Toledano H; Larouche V; Kline C; Abdelbaki MS; Jabado N; Gottardo NG; Gerber NU; Whipple NS; Segal D; Chi SN; Oren L; Tan EEK; Mueller S; Cornelio I; McLeod L; Zhao X; Walter A; Da Costa D; Manley P; Blackman SC; Packer RJ; Nysom K
Nat Med; 2024 May; 30(5):1500. PubMed ID: 38467878
[No Abstract] [Full Text] [Related]
3. How will tovorafenib change our treatment of pediatric low-grade glioma?
Yaman I; Bouffet E
Expert Opin Emerg Drugs; 2024 Mar; 29(1):1-3. PubMed ID: 38293894
[No Abstract] [Full Text] [Related]
4. BRAF-Targeted Therapy in the Treatment of
Johanns TM; Ansstas G; Dahiya S
J Natl Compr Canc Netw; 2018 Apr; 16(4):451-454. PubMed ID: 29632063
[No Abstract] [Full Text] [Related]
5. Targeted Therapy Win in BRAF-Mutant Gliomas.
Cancer Discov; 2023 Nov; 13(11):2299-2300. PubMed ID: 37732735
[TBL] [Abstract][Full Text] [Related]
6. Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.
Raswoli M; Nobre L; Hawkins C; Bartels UK; Tabori U; Bouffet E
Pediatr Blood Cancer; 2021 Jan; 68(1):e28561. PubMed ID: 32681754
[No Abstract] [Full Text] [Related]
7. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Kilburn LB; Khuong-Quang DA; Hansford JR; Landi D; van der Lugt J; Leary SES; Driever PH; Bailey S; Perreault S; McCowage G; Waanders AJ; Ziegler DS; Witt O; Baxter PA; Kang HJ; Hassall TE; Han JW; Hargrave D; Franson AT; Yalon Oren M; Toledano H; Larouche V; Kline C; Abdelbaki MS; Jabado N; Gottardo NG; Gerber NU; Whipple NS; Segal D; Chi SN; Oren L; Tan EEK; Mueller S; Cornelio I; McLeod L; Zhao X; Walter A; Da Costa D; Manley P; Blackman SC; Packer RJ; Nysom K
Nat Med; 2024 Jan; 30(1):207-217. PubMed ID: 37978284
[TBL] [Abstract][Full Text] [Related]
8. Tovorafenib effective against low-grade gliomas harbouring BRAF fusions.
Sidaway P
Nat Rev Clin Oncol; 2024 Feb; 21(2):83. PubMed ID: 38082106
[No Abstract] [Full Text] [Related]
9. To BRAF or not to BRAF: is that even a question anymore?
Horbinski C
J Neuropathol Exp Neurol; 2013 Jan; 72(1):2-7. PubMed ID: 23242278
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis.
Kai Z; Dingyang L; Zhuanyi Y
World Neurosurg; 2021 Mar; 147():42-46. PubMed ID: 33316486
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers in adult gliomas: the present and the future.
Thomas L; Di Stefano AL; Ducray F
Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
